SCM
MRNA icon

Stevens Capital Management’s Moderna MRNA Stock Holding History

Stevens Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,426
Closed -$739K – 325
2023
Q4 		$739K Sell
7,426
-28,660
-79% -$2.41M 0.18% 117
2023
Q3 		$3.73M Buy
36,086
+23,583
+189% +$2.63M 1.08% 16
2023
Q2 		$1.52M Sell
12,503
-27,374
-69% -$3.65M 0.31% 70
2023
Q1 		$6.12M Buy
39,877
+29,724
+293% +$4.9M 1.52% 15
2022
Q4 		$1.82M Buy
+10,153
New +$1.66M 1.15% 22
2022
Q3 		– Sell
-54,154
Closed -$7.74M – 165
2022
Q2 		$7.74M Buy
54,154
+31,427
+138% +$4.49M 5.38% 5
2022
Q1 		$3.92M Buy
22,727
+164
+0.7% +$27.6K 0.85% 28
2021
Q4 		$5.73M Buy
+22,563
New +$6.6M 1.32% 19
2019
Q3 		– Sell
-75,249
Closed -$1.1M – 687
2019
Q2 		$1.1M Buy
+75,249
New +$1.62M 0.05% 351

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens Capital Management's MRNA Position: Q1 2024 in Review

Stevens Capital Management sold out of Moderna (MRNA) in Q1 2024, closing a stake of 7,426 shares — an estimated $739K sold.

Stevens Capital Management first reported a position in MRNA in Q2 2019 and held it in 9 quarters. The position peaked at $7.74M in Q2 2022. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Stevens Capital Management reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Stevens Capital Management sold 7,426 Moderna shares in Q1 2024, an estimated $739K.
  • Stevens Capital Management first reported a position in Moderna in Q2 2019 and held it in 9 quarters.
  • Stevens Capital Management's Moderna position peaked at $7.74M in Q2 2022.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Stevens Capital Management's 13F filing for Q1 2024, filed 8 May 2024.